Physician profile
Suresh Chode
NPI 1336378934
$1,732.78
in general payments reported to CMS, 2019-2025
21 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $14.68 · 2022: $57.15 · 2023: $103 · 2024: $473 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.62 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $208.82 | 2022-2025 | Minimed 780g |
| Radius Health, INC. | $177.97 | 2024-2025 | Tymlos |
| Abbott Laboratories | $165.73 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $136.49 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $128.63 | 2024-2025 | |
| Medtronic Minimed, INC. | $125.00 | 2019 | |
| Amgen INC. | $87.96 | 2024-2025 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $68.12 | 2024-2025 | Recorlev |
| Lilly USA, LLC | $64.35 | 2023-2025 | Mounjaro, Zepbound |
| Sequel Med Tech, LLC | $54.58 | 2025 | Twiist |
| Dexcom, INC. | $43.75 | 2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $43.23 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $42.49 | 2025 | Qutenza |
| Recordati_rare_diseases_inc. | $33.71 | 2025 | Isturisa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.74 | 2025 | |
| Esperion Therapeutics, INC. | $27.68 | 2024 | Nexletol |
| Ascensia Diabetes Care US INC. | $26.53 | 2025 | |
| Neurocrine Biosciences, INC. | $24.27 | 2025 | |
| Beta Bionics, INC. | $18.43 | 2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Chode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.